Formulation Development
Oncovita & Institut Pasteur Announce Creation of Joint Laboratory Dedicated to Cancer Immunotherapy & Prophylactic Vaccinology
Dedicated to the research of new immunotherapeutic vaccines in oncology and prophylactic vaccines for contagious diseases, the joint Institut Pasteur - Oncovita laboratory is aimed…
Secarna Pharmaceuticals & Orbit Discovery Enter Collaboration to Discover & Develop Peptide-Conjugated Targeted Antisense Oligonucleotide Therapeutics
New platform capabilities extend the reach of Secarna’s antisense approaches, potentially offering new treatment options for a wider range of diseases….
Asahi Kasei to Acquire Calliditas Therapeutics AB to Accelerate Growth as a Global Healthcare Company
Asahi Kasei Corp. recently announced it will offer the shareholders of Calliditas Therapeutics AB to acquire the shares of the pharmaceutical company Calliditas for the purpose of….
selectION Announces Initiation of Phase 1b Clinical Trial Evaluating si-544 in Patients With Psoriasis Vulgaris or Psoriatic Arthritis
selectION, Inc. recently announced the initiation of a Phase 1b trial with its lead compound si-544 in adult patients with psoriasis vulgaris (Ps) or psoriatic…
Agios Announces $905-Million Purchase Agreement for Vorasidenib Royalty
Agios Pharmaceuticals, Inc. recently announced it has agreed to sell its rights to its 15% royalty on potential US net sales of Servier’s vorasidenib to….
GlycoNex & PrecisemAb Sign Technology Licensing Agreement to Advance Development of Novel Anti-Glycan Antibodies for Cancer Therapy
GlycoNex to advance development of novel pro-antibody cancer drugs that enhance tumor suppression while minimizing off-site binding to healthy tissues to improve safety and tolerability….
CARGO Therapeutics Announces $110-Million Private Placement Equity Financing
CARGO Therapeutics, Inc. recently announced it has entered into a securities purchase agreement for a private investment in public equity financing that is expected to…
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism
Corcept Therapeutics Incorporated recently announced that GRACE, the Phase 3 trial of its proprietary selective cortisol modulator relacorilant in patients with hypercortisolism (Cushing’s syndrome), met…
BriaCell Announces Clinical Supply Agreement With BeiGene for Bria-OTS First in Human Study
BriaCell Therapeutics Corp. recently announced a clinical supply agreement with BeiGene, Ltd. to evaluate the safety and efficacy of Bria-OTS, BriaCell’s next generation immunotherapy, in…
Vetter Wins Best Managed Companies Award 2024
Vetter has once again been awarded the Best Managed Companies Award, marking its fifth consecutive win. The jury made its selection based on Vetter’s consistency…
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 in Patients With Alzheimer’s Disease
Coya Therapeutics, Inc. recently announced the completion of a randomized, double-blind, placebo-controlled Phase 2 study of LD IL-2 in patients with mild-to-moderate AD. The study…
Amphista Therapeutics Unveils New Differentiated Mechanism of Action for BRD9 Degradation
Amphista’s bifunctional BRD9 degraders selectively induce BRD9 to DCAF16 proximity and serve as molecular glues, leading to strong and rapid degradation of BRD9….
TFF Pharmaceuticals & Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program Into Preclinical Testing
TFF Pharmaceuticals, Inc. recently announced the government will be advancing several next-generation medical countermeasures (MCMs) formulated with its Thin Film Freezing technology into advanced preclinical…
Pneumagen Presents Positive Phase 2 Influenza Human Challenge Study Data
Pneumagen recently presented positive results from its Phase 2, proof-of-concept, Controlled Human Infection Model (CHIM) study in which healthy volunteers were challenged with influenza virus…
Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for Descartes-08 for the Treatment of Myasthenia Gravis
Cartesian Therapeutics, Inc. recently announced the US FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation for Descartes-08 for the treatment of myasthenia gravis (MG).…
Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid Tumors
Indaptus Therapeutics, Inc. recently announced the successful advancement of its Phase 1 trial for Decoy20, an investigational novel package of broad immune agonists for cancer…
First-In-Class Cholesterol-Lowering Treatment & its Combination With Ezetimibe Approved In Europe to Treat Hypercholesterolemia & Significantly Reduce Cardiovascular Risk
Daiichi Sankyo Europe GmbH and Esperion Therapeutics, Inc. jointly announced the European Commission (EC) has approved the label update of both NILEMDO (bempedoic acid) and…
AGC Biologics & BioConnection Partner to Offer New End-to-End Biopharmaceutical Drug Substance & Drug Product Development & Manufacturing Offering
AGC Biologics and BioConnection recently announced a new strategic partnership. The companies are partnering to provide end-to-end biopharmaceutical development and manufacturing capabilities for drug substance…
Asymchem Secures Former Pfizer Development & API Pilot Plant Manufacturing Facilities
Asymchem Laboratories (Tianjin) Co., Ltd. recently announced today it will operate the former Pfizer UK small molecule API pilot plant and part of the development…
Alvotech & Dr. Reddy’s Enter Commercialization Collaboration
Alvotech and Dr. Reddy’s Laboratories SA recently announced the companies have entered into a license and supply agreement for the commercialization of AVT03, Alvotech’s biosimilar candidate to….